Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NUVL
SELLNuvalent, Inc. · Healthcare · United States · $9.8B · Avg Vol: $483M/d
COMPANY DESCRIPTION
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely designed, small molecule kinase inhibitors for patients with cancer. Its proprietary drug discovery platform enables the development of highly selective and potent therapies that can overcome resistance mechanisms in difficult-to-treat mutations. The company's innovative approach aims to address critical unmet needs in targeted oncology.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | 10.7M | 181.0M | — |
| EPS | -2.13 | -1.65 | -2.17 | -3.93 | -5.85 | — | -6.06 | -5.50 | -4.02 | — |
| Shares | — | 56.7M | 64.1M | 71.3M | 78.2M | +38.1% | 73.7M | — | — | — |
| Debt | — | — | — | — | — | — | — | — | — | — |
| Equity | — | 463.0M | 700.6M | 1.1B | 1.2B | 39.2% | — | — | — | — |
| Op CF | — | -65.0M | -99.7M | -185.1M | -275.2M | — | -312.8M | — | — | — |
| Inv CF | — | -10.7M | -143.5M | -573.5M | -124.1M | — | — | — | — | — |
| Fin CF | — | 248.9M | 336.8M | 568.9M | 515.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NUVL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NUVL | Nuvalent, Inc.(you) | $9.8B | 30 | SELL |
| PRAX | Praxis Precision Medicines, Inc. | $9.1B | 29 | SELL |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.9B | 30 | SELL |
| SYRE | Spyre Therapeutics, Inc. | $8.9B | 32 | SELL |
| KYMR | Kymera Therapeutics, Inc. | $9.1B | 25 | SELL |
| CYTK | Cytokinetics, Incorporated | $11.0B | 26 | SELL |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.0B | 30 | SELL |
| PCVX | Vaxcyte, Inc. | $7.9B | 27 | SELL |
| ERAS | Erasca, Inc. | $6.6B | 31 | SELL |
| IBRX | ImmunityBio, Inc. | $7.4B | 26 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.6%